Short-Term Therapy with Rosiglitazone, a PPAR- Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats
Figure 1
The effects of (a) KCl (10–125 mM) and (b) noradrenaline (NA; 0.5–6 μM) on arteries from 5-day rosiglitazone-treated and untreated control animals. There were no significant differences between the two groups. Data represent mean ± S.E.M.
